The FDA issued new guidelines to speed up the review process for gene therapies; a new report calculates the potential societal benefits of eliminating the opioid epidemic; and one-third of Americans are unaware that the ACA's open enrollment season has begun.
New guidelines will speed up the FDA’s review of gene therapies to get these treatments to market faster. The agency will still require clinical trials, but the process will be faster for these novel therapies, reported The New York Times. In addition, the FDA said it will increase oversight of clinics offering dangerous or unproven versions of treatments involving human cells and tissues. Unregulated procedures have been offered to treat arthritic knees, back pain, heart disease, and other problems.Preventing opioid overdoses, deaths, and substance-use disorders could have saved $95 billion in 2016, according to a new report. The research brief from Altarum calculated the societal benefits of eliminating the epidemic based on productivity gains from saving lives and reducing substance use, averting healthcare costs, and reducing spending on other services that help address the opioid epidemic. In 2016, deaths related to opioids, heroin, fentanyl, and related drugs reached more than 53,000.Nearly one-third of all people are that open enrollment for the Affordable Care Act has begun. Kaiser Health News reported that, despite the high number of people unaware of the enrollment dates, which includes one-third of uninsured people, open enrollment is off to a strong start. So far, 1.5 million people have enrolled through HealthCare.gov. The shorter enrollment season, which is just 45 days this year, may be pushing people to sign up earlier.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More